Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakır O, Dundar M, Yucesoy M. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6(8): 613-620 [PMID: 25232454 DOI: 10.4254/wjh.v6.i8.613]
Corresponding Author of This Article
Mehmet Celikbilek, MD, Department of Gastroenterology, Erciyes University, Medical School, 38039 Kayseri, Turkey. drcelikbilek@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Aug 27, 2014; 6(8): 613-620 Published online Aug 27, 2014. doi: 10.4254/wjh.v6.i8.613
Table 1 Clinical and demographic characteristics of non-alcoholic fatty liver disease patients and controls
Variable
NAFLD (n = 20)
Control (n = 20)
P
Age (yr)
42.75 ± 8.17
44.50 ± 9.31
0.761
Sex (male/female)
9 (45.0)/11(55.0)
9 (45.0)/11 (55.0)
0.761
BMI (kg/m2)
31.86 ± 4.76
27.26 ± 3.07
0.006
Waist circumference (cm)
103.25 ± 13.65
90.75 ± 11.02
0.014
Systolic blood pressure (mmHg)
120.25 ± 8.66
120.25 ± 7.69
0.999
Diastolic blood pressure (mmHg)
76.50 ± 6.09
77.50 ± 8.96
0.761
Fasting glucose (mg/dL)
97.85 ± 13.88
86.80 ± 11.92
0.034
Triglycerides (mg/dL)
151.10 ± 65.06
167.70 ± 51.46
0.645
HDL-C (mg/dL)
43.00 (36.50-48.50)
45.00 (38.45-49.95)
0.761
LDL-C (mg/dL)
125.50 (100.00-139.00)
108.00 (89.25-121.25)
0.511
Insulin (mIU/mL)
14.81 (11.88-22.75)
11.76 (8.61-15.70)
0.229
HOMA-IR
4.05 (2.71-5.51)
2.21 (1.77-3.12)
0.034
Total biluribin (mg/dL)
0.65 (0.50-0.80)
0.60 (0.55-0.80)
0.761
Direct biluribin (mg/dL)
0.20 (0.12-0.25)
0.20 (0.10-0.20)
0.761
AST (IU/L)
45.00 (34.50-59.00)
21.00 (18.00-27.00)
< 0.001
ALT (IU/L)
68.50 (52.50-85.50)
18.50 (14.00-29.00)
< 0.001
AP (IU/L)
76.00 (55.50-96.00)
69.00 (57.00-78.50)
0.761
GGT (IU/L)
48.00 (33.00-73.00)
20.00 (14.50-33.00)
< 0.001
Creatinine (mg/dL)
0.87 ± 0.15
0.80 ± 0.18
0.401
WBC (μL)
6709.50 ± 1709.47
6618.00 ± 1425.37
0.892
Trombocyte (103/μL)
252.10 ± 64.85
275.90 ± 69.82
0.511
Hct
43.37 ± 3.53
44.25 ± 4.19
0.761
Table 2 Log2 (Fold change) ratios of differentially expressed miRNAs which were statistically significant by t test (P < 0.05) and further confirmed by SAM test (q < 5%)
miRNAs
log2 (Fold change)
q value (%)
Mean
SEM
Over-expressed
-
-
-
-
Under-expressed
miR-197
-1.61
0.54
0
miR-146b
-1.52
0.55
0
miR-181d
-2.49
0.50
0
miR-99a
-1.92
0.53
0
Table 3 Point-biserial correlation coefficients between NAS-scale parameters and miRNAs in non-alcoholic fatty liver disease patients
Table 5 Statistical diagnostic measures for miR-197, miR-146b, miR-181d and miR-99a in identifying non-alcoholic fatty liver disease
miRNA
Cut-off value
SEN (95%CI)
SPE (95%CI)
PPV (95%CI)
NPV (95%CI)
miR-197
≤ -1.0144
60.0 (36.1-80.9)
95.0 (75.1-99.9)
92.3 (64.0-99.8)
70.4 (49.8-86.2)
miR-146b
≤ -0.7689
55.0 (31.6-76.9)
100.0 (83.0-100.0)
100.0 (71.3-100.0)
69.0 (49.2-84.7)
miR-181d
≤ -0.2861
70.0 (45.7-88.0)
85.0 (62.1-96.6)
82.4 (56.6-96.0)
73.9 (51.6-89.7)
miR-99a
≤ -0.1562
65.0 (40.8-84.5)
95.0 (75.1-99.2)
92.9 (66.1-98.8)
73.1 (52.2-88.4)
Citation: Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakır O, Dundar M, Yucesoy M. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6(8): 613-620